logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
    • Investors
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us
glycotest_logo
logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
    • Investors
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us

Glycotest Announces Grant of US Patent Extending Coverage of Its Fucosylated Biomarker Diagnostic Technology for Serious Liver Disease

September 25, 2018
-
News
-
No comments
-
Posted by glycotest
← PREVIOUS POST
Glycotest™ Closes $10 Million Series A Financing with Fosun Pharma
NEXT POST →
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Related News

Other posts that you should not miss.

Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent.

January 13, 2021
-
News
Read More →
Posted by glycotest
1 MIN READ

Six new patents protecting Glycotest’s HCC Panel test have been issued or allowed in the United States, Europe, China, Taiwan, Japan, and Mexico.

March 1, 2023
-
News
Read More →
Posted by glycotest
1 MIN READ

More than 50 Glycotest Fucosylated Biomarkers Protected through Grant of New US Patent.

November 3, 2020
-
News
Read More →
Posted by glycotest
1 MIN READ

GET IN TOUCH

Give Us A Call

+1 484-431-3483

Send Us A Message

info@glycotest.com

Copyright© All Rights Reserved
Website Designed & Developed by Jason and Company
Glycotest Announces Grant of US Patent Extending Coverage of Its Fucosylated Biomarker Diagnostic Technology for Serious Liver Disease | Glycotest Diagnostics